Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- August31 2004
- Volume 11
- Issue 16
Wealth-Friendly States
Author(s)Michael Sheehan
Advertisement
Bloomberg Wealth Manager
Which of our 50 states do a better job of promoting wealth for its families (ie, provide a fair tax environment, treat retirees well, promote prosperity, effectively manage taxpayers' money, and offer a solid economic atmosphere). According to , the following states receive the best and worst wealth-friendly grades from 2000 to 2004:
Articles in this issue
about 18 years ago
Take Charge of Your Retirement Rolloverabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Investigate Age-Related Benefit Changesabout 18 years ago
Take a Sneak Peak at an Unknown Productabout 18 years ago
Share in Constan's Millionsabout 18 years ago
Navigate Past Bond Investing Stereotypesabout 18 years ago
Consider the Value of Passive Investingabout 18 years ago
Unfold an Online Stock Research Roadmapabout 18 years ago
Where Should You Invest as Rates Rise?about 18 years ago
Create Your Investment Policy StatementAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5